Institution
Oswaldo Cruz Foundation
Facility•Rio de Janeiro, Brazil•
About: Oswaldo Cruz Foundation is a facility organization based out in Rio de Janeiro, Brazil. It is known for research contribution in the topics: Population & Trypanosoma cruzi. The organization has 18673 authors who have published 36752 publications receiving 802378 citations. The organization is also known as: Fundação Oswaldo Cruz & FIOCRUZ.
Topics: Population, Trypanosoma cruzi, Immune system, Public health, Health care
Papers published on a yearly basis
Papers
More filters
TL;DR: The literature on the concept and measurement of race is reviewed and how the findings apply to the United States and Brazil are compared and recommendations are made about the measurement ofrace in medical records and public health research.
Abstract: Race has been widely used in studies on health and healthcare inequalities, especially in the United States. Validity and reliability problems with race measurement are of concern in public health. This article reviews the literature on the concept and measurement of race and compares how the findings apply to the United States and Brazil. We discuss in detail the data quality issues related to the measurement of race and the problems raised by measuring race in multiracial societies like Brazil. We discuss how these issues and problems apply to public health and make recommendations about the measurement of race in medical records and public health research.
210 citations
210 citations
TL;DR: Regimens containing once-daily ATV/RTV demonstrated comparable efficacy and safety, with significant reductions in total cholesterol and fasting triglycerides and improved gastrointestinal-tolerability in comparison with twice-daily regimens containing LPV/ RTV over 96 weeks in treatment-experienced patients.
Abstract: Background: In BMS Study 045, once-daily (QD) atazanavir/ritonavir (ATV/RTV) demonstrated comparable efficacy and safety to twice-daily (BID) lopinavir/ritonavir (LPV/RTV) over 48 weeks in treatment-experienced patients. Results of extended follow-up to 96 weeks are presented. Methods: BMS Study 045 was an open-label, randomized, multi-national trial of HIV-infected patients with virologic failure on two or more prior HAART regimens designed to evaluate the efficacy and safety of ATV/RTV (300/100 mg) QD and LPV/RTV (400/ 100 mg) BID, each with tenofovir (300 mg) QD and one nucleoside reverse transcriptase inhibitor. The primary efficacy measure was the time-averaged difference (TAD) in reduction in HIV RNA from baseline. Secondary objectives included evaluation of safety and plasma lipid levels through week 96. Results: Over 96 weeks, the ATV/RTV regimen demonstrated similar virologic efficacy to the LPV/RTV regimen. Mean reductions from baseline in HIV RNA were -2.29 and -2.08 log 10 copies/ml, respectively [TAD (97.5% confidence interval): 0.14 log 10 copies/ml (-0.13, 0.41)]. The LPV/RTV regimen resulted in significant increases in total cholesterol (+9%) and fasting triglycerides (+30%) in comparison with the ATV/ RTV regimen, which demonstrated decreases in these parameters [-7 and -2%, respectively, (P < 0.0001)]. Grade 2-4 diarrhoea occurred less frequently in ATV/ RTV patients (3%) in comparison with LPV/RTV patients (13%) (P < 0.01). Grade 3-4 elevations in bilirubin were more common in ATV/RTV patients (53%) than LPV/RTV patients (< 1%) (P < 0.0001), with no resulting discontinuations. Conclusions: Regimens containing once-daily ATV/RTV demonstrated comparable efficacy and safety, with significant reductions in total cholesterol and fasting triglycerides and improved gastrointestinal-tolerability in comparison with twice-daily regimens containing LPV/RTV over 96 weeks in treatment-experienced patients.
210 citations
TL;DR: In this paper, the incorporation of Brazilian elemi, a highly hydrophobic resinous exudate of the botanical family Burseraceae, into gelatin films, using a blend of stearic and palmitic acids to dissolve the elemi and subsequent emulsification of the filmogenic solution using triacetin as plasticizer.
209 citations
University of New Mexico1, Washington University in St. Louis2, University of Aberdeen3, George Washington University4, University of the District of Columbia5, Oswaldo Cruz Foundation6, Silver Spring Networks7, Medical University of South Carolina8, Brunel University London9, Centre national de la recherche scientifique10, Oregon State University11, University of Wisconsin-Madison12, Carleton University13, Iowa State University14, Harvard University15, Sunnybrook Health Sciences Centre16, University of Utah17, New Mexico State University18, Aberystwyth University19, European Bioinformatics Institute20, IFREMER21, University of the Sunshine Coast22, Peter MacCallum Cancer Centre23, Walter and Eliza Hall Institute of Medical Research24, University of Notre Dame25, University of Copenhagen Faculty of Science26, National Institutes of Health27, Bowling Green State University28, University of Alberta29, Lawrence University30, University of Göttingen31, Pennsylvania State University32, VU University Amsterdam33, Whitney Laboratory for Marine Bioscience34, Kingston University35, QIMR Berghofer Medical Research Institute36, Kenya Medical Research Institute37, University of Pennsylvania38, Lawrence Berkeley National Laboratory39, University of California, Santa Cruz40, American Museum of Natural History41, University of Westminster42, London Centre for Nanotechnology43, Rutherford Appleton Laboratory44
TL;DR: Parts of phero-perception, stress responses, immune function and regulation of gene expression that support the persistence of B. glabrata are described and several potential targets for developing novel control measures aimed at reducing snail-mediated transmission of schistosomiasis are identified.
Abstract: Biomphalaria snails are instrumental in transmission of the human blood fluke Schistosoma mansoni With the World Health Organization's goal to eliminate schistosomiasis as a global health problem by 2025, there is now renewed emphasis on snail control Here, we characterize the genome of Biomphalaria glabrata, a lophotrochozoan protostome, and provide timely and important information on snail biology We describe aspects of phero-perception, stress responses, immune function and regulation of gene expression that support the persistence of B glabrata in the field and may define this species as a suitable snail host for S mansoni We identify several potential targets for developing novel control measures aimed at reducing snail-mediated transmission of schistosomiasis
209 citations
Authors
Showing all 18833 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Douglas T. Golenbock | 123 | 317 | 61267 |
| Guy A. Zimmerman | 109 | 328 | 39740 |
| David Brown | 105 | 1257 | 46827 |
| Liam Smeeth | 104 | 753 | 53433 |
| Ann M. Dvorak | 99 | 437 | 41073 |
| David C. Spray | 95 | 400 | 28732 |
| Theodore A. Slotkin | 89 | 575 | 30070 |
| Fernando Q. Cunha | 88 | 682 | 31501 |
| Mauro M. Teixeira | 86 | 713 | 31301 |
| Ricardo T. Gazzinelli | 86 | 340 | 28233 |
| Peter F. Weller | 85 | 331 | 22005 |
| João B. Calixto | 81 | 460 | 23029 |
| Frederic J. Seidler | 80 | 372 | 19564 |
| João Santana da Silva | 80 | 399 | 19060 |
| Deborah Carvalho Malta | 77 | 706 | 61000 |